We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An FDA advisory committee voted to Friday in favor of the risk-benefit profile of Aimmune Therapeutics’ peanut allergy therapy Palforzia (AR101). Read More
Purdue’s tentative $12 billion settlement for its role in the opioid abuse crisis sparked strong reactions from attorneys general across the country who believe the states deserve better. Read More
Higher percentages of new cancer drug approvals received priority ratings from the FDA and had orphan drug status during 1999-2018, compared to new non-cancer drugs. Read More